227
Participants
Start Date
April 15, 2020
Primary Completion Date
December 1, 2020
Study Completion Date
April 1, 2021
Gimsilumab
Gimsilumab is a fully human monoclonal antibody (mAb).
Placebo
Normal saline
Mount Sinai Beth Israel, New York
Mount Sinai West, New York
Mount Sinai Morningside, New York
Icahn School of Medicine at Mount Sinai, New York
Jamaica Hospital Medical Center, Jamaica
Temple University Hospital, Philadelphia
Inova Fairfax Medical Campus, Falls Church
Piedmont Healthcare, Atlanta
Emory University School of Medicine, Atlanta
University of Florida, Gainesville
Miami Cancer institute, Miami
Vanderbilt University Medical Center, Nashville
University Hospitals Cleveland Medical Center, Cleveland
Beaumont Hospital - Royal Oak, Royal Oak
NorthShore University HealthSystem, Evanston
East Jefferson General Hospital, Metairie
Baylor Scott & White All Saints Medical Center, Fort Worth
Baylor Scott & White Medical Center, Irving
Baylor Scott & White Heart Hospital, Plano
Baylor Scott & White Medical Center, Plano
Baylor Jack & Jane Hamilton Heart and Vascular Hospital, Dallas
Baylor University Medical Center, Dallas
Baylor Scott & White Medical Center, Temple
Memorial Hermann Hospital Affiliated with University of Texas Health Science Center at Houston, McGovern Medical School, Houston
Baylor Scott & White Medical Center, Round Rock
Banner University Medical Center, Phoenix
HonorHealth John C. Lincoln Medical Center, Phoenix
HonorHealth Scottsdale Osborn Medical Center, Scottsdale
HonorHealth, Scottsdale
HonorHealth Scottsdale Shea Medical Center, Scottsdale
Banner University Medical Center, Tucson
UCLA Ronald Reagan Medical Center, Los Angeles
Brigham and Women's Hospital, Boston
Lead Sponsor
Roivant Sciences, Inc.
INDUSTRY
Kinevant Sciences GmbH
INDUSTRY